Mavacoxib

Osteoarthritis is a chronic degenerative joint disease, with the number of patients worldwide exceeding 500 million. Recurrent pain and inflammation are the core triggers affecting patients' quality of life. Mavacoxib is a second-generation selective cyclooxygenase-2 (COX-2) inhibitor. By specifically blocking the prostaglandin synthesis pathway mediated by COX-2, it exerts potent anti-inflammatory and analgesic effects while greatly reducing the risk of gastrointestinal adverse reactions common with traditional non-steroidal anti-inflammatory drugs. At present, it is mainly used to relieve pain and inflammatory symptoms related to canine osteoarthritis, and is a commonly used anti-inflammatory and analgesic drug in the field of companion animal diagnosis and treatment.

The global veterinary anti-inflammatory and analgesic drug market exceeded US$9 billion in 2023. Among them, the selective COX-2 inhibitor segment, to which mavacoxib belongs, maintains a compound annual growth rate of around 8%, making it one of the fast-growing categories in veterinary prescription drugs. Currently, the global market is still dominated by original research products, with Europe and North America being the main consumption regions. Domestic veterinary chemical drug enterprises are gradually deploying the generic development of this variety. With the continuous growth of domestic pet medical consumption demand, the market application space of mavacoxib will further expand.

The original research enterprise of mavacoxib is Boehringer Ingelheim, and the original trade name is Previcox. Its core compound patent expired in the European Union in 2024, and the core patent in the US market will expire in 2025. The main dosage form of the original research marketed product is oral tablet, with common specifications including 57mg and 227mg, which has been included in the FDA Reference Listed Drug Directory for Animal Drugs. Up to now, no domestic enterprise has submitted the CDE registration number for mavacoxib API, and there is no domestically produced mavacoxib preparation product approved for marketing. The imported original research preparation is the only supply source in the current domestic market. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for mavacoxib API, which can fully cover the reference substance requirements in all links of API R&D, quality research, and registration declaration. Most products are available from stock. For in-stock orders placed before 16:00, they can be shipped on the same day. All products comply with the regulatory requirements of drug regulatory authorities of various countries such as the Chinese Pharmacopoeia and FDA, helping enterprises to rapidly advance the R&D and registration process.